OMC
TLX

Old Mission Capital’s Telix Pharmaceuticals TLX Stock Holding History

Old Mission Capital’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,799
Closed -$111K – 1355
2025
Q4 		$111K Buy
+14,799
New +$142K ﹤0.01% 965

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Old Mission Capital's TLX Position: Q1 2026 in Review

Old Mission Capital sold out of Telix Pharmaceuticals (TLX) in Q1 2026, closing a stake of 14,799 shares — an estimated $111K sold.

Old Mission Capital first reported a position in TLX in Q4 2025 and held it in 1 quarter. The position peaked at $111K in Q4 2025. 39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

  • Old Mission Capital reported no remaining Telix Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Old Mission Capital sold 14,799 Telix Pharmaceuticals shares in Q1 2026, an estimated $111K.
  • Old Mission Capital first reported a position in Telix Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Old Mission Capital's Telix Pharmaceuticals position peaked at $111K in Q4 2025.
  • 39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on Old Mission Capital's 13F filing for Q1 2026, filed 15 May 2026.